Scandinavian Starch for Severe Sepsis/Septic Shock Trial
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
- By tradition hydroxyethyl starch (HES) is used to obtain fast circulatory stabilisation
in critically ill.
- High molecular weight HES may, however, cause acute kidney failure in patients with
severe sepsis.
- Now the low molecular weight HES 130/0.4 is the preferred colloid in Scandinavian
intensive care units (ICU) and 1st choice fluid for patients with severe sepsis.
- HES 130/0.4 is largely unstudied in ICU patients.
- This investigator-initiated Scandinavian multicentre trial will be conducted to assess
the effects of HES 130/0.4 on mortality and endstage kidney failure in patients with
severe sepsis.
- The trial will provide important data to all clinicians who resuscitate septic patients.
Phase:
Phase 3
Details
Lead Sponsor:
Anders Perner
Collaborators:
B. Braun Melsungen AG Copenhagen Trial Unit, Center for Clinical Intervention Research Rigshospitalet, Denmark University of Copenhagen